title: A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG).
abstract: Radiolabelled meta-iodobenzylguanidine (MIBG) is widely used in the diagnosis, follow-up and treatment of patients with tumours of neural crest origin. Some commonly prescribed and readily available over-the-counter medicines interfere with the uptake and biodistribution of this radiopharmaceutical. This may lead to poor concentration of radiolabelled MIBG within the target organs and tissues. The clinical implications are a potentially inaccurate assessment of tumour burden during diagnostic studies and a suboptimal radiation dose when MIBG is employed for targetted radiotherapy. In order to avoid false negative results a comprehensive list of prescribed and over-the-counter medicines that have the potential to inhibit uptake of MIBG has been compiled. It is hoped that this will help nuclear medicine physicians to avoid this pitfall.
authors.affiliation: Department of Nuclear Medicine, St Bartholomew's Hospital, London, UK.
authors.forename: K K
authors.initials: KK
authors.lastname: Solanki
authors.forename: J
authors.initials: J
authors.lastname: Bomanji
authors.forename: J
authors.initials: J
authors.lastname: Moyes
authors.forename: S J
authors.initials: SJ
authors.lastname: Mather
authors.forename: P J
authors.initials: PJ
authors.lastname: Trainer
authors.forename: K E
authors.initials: KE
authors.lastname: Britton
mesh_terms: D019797:3-Iodobenzylguanidine; D004347:Drug Interactions; D006801:Humans; D007457:Iodine Radioisotopes; D007462:Iodobenzenes / Q000493:pharmacokinetics*; D004366:Nonprescription Drugs
chemical_list: D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D004366:Nonprescription Drugs; D019797:3-Iodobenzylguanidine